Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)

Annals of the Rheumatic Diseases

Volumn 61, Issue SUPPL. 2, 2002, Pages

  Furst, D E ^a   Kavanaugh, A ⁱ   Klareskog, L ^j   Breedveld, F C ^b   Kalden, J R ^c   Smolen, J S ^d   Antoni, C E ^c   Bijlsma, J W J ^e   Burmester, G R ^f   Cronstein, B ^g   Keystone, E C ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MOUNT SINAI HOSPITAL   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

APLASTIC ANEMIA; BACTERIAL INFECTION; CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; MYCOSIS; PANCYTOPENIA; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

EID: 0036838681     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Consensus group. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001;60(suppl III):iii2-5.
2. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: Developing guidelines. BMJ 1999;318:593-6.
3. Wolfe F, Pincus T, O'Dell J. Arthritis disease status in the clinic: Which variables best predict change in therapy? J Rheumatol 2001;28:1712-17.
4. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
5. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
6. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
7. Elliott MJ, Maini RN, Feldmann M, Ka den JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
8. Furst DE, Keystone E, Maini RN, Smolen JS. Recapitulation of the round-table discussion - Assessing the role of anti-tumor necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 1999;38(suppl 2):50-53.
9. Garrison L, McDonnell ND. Etanercept: Therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58(suppl 1):165-9.
10. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF(alpha) treatment. Ann Rheum Dis 1999;58(suppl 1):161-4.
11. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999;48:1-3.
12. Kavanaugh AF. Anti-tumor necrosis factor alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998;24:593-614.
13. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
14. Markham A, Lamb HM. Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
15. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
16. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatid arthritis. A randomized controlled trial. Ann Intern Med 1999;130:478-86.
17. Moreland LW, Margolies G, Heck Jr. LW, Saway A, Blosch C, Hanna R, et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996;23:1849-55.
18. Cush JJ, Spiera R. Etanercept update on recent "dear doctor" safety letter. ACR Hotline Dec 5, 2000.
19. Bray VJ. The safety of infliximab infusion in clinical practice. Arthritis Rheum 2001;44(suppl):S83 (abs 183).
20. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Noctor JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9.
21. Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
22. Mease P, Goffe B, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis. Lancet 2000;356:385-90.
23. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002;359:1187-93.
24. Baeten D, Demetter P, Kruithof E, et al. Effect of TNF alpha blockade on synovial histology in spondyloarthropathy. Arthritis Rheum 2000;43(suppl):S404 (abs 2022).
25. Gorman JD, Sack KE, Davis JC, et al. Etanercept in the treatment of ankylosing spondylitis: A randomized, double-blind, placebo-controlled study. Arthritis Rheum 2000;44(suppl):S403 (abs 2020).
26. Brandt J, Haibel H, Reddig J, et al. Anti-TNF alpha treatment of patients with severe ankylosing spondylitis - A one year follow-up. Arthritis Rheum 2000;44(suppl):S403 (abs2021).
27. Weinblatt ME, Maier AI, Overman SS, et al. Etanercept in Still's disease in the adult. Arthritis Rheum 2000;43(suppl)::S391 (abs 1949).
28. Kraetsch HG, Antoni C, Kalden JR, Manger B. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab. Arthritis Rheum 2001;44(suppl):S118 (abs 395).
29. Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNF alpha blocking treatment. Ann Rheum Dis 2002;61:283-4.
30. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight threatening pan uveitis in Behcet's disease. Lancet 2001;358:295-6.
31. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjögren's syndrome: A pilot study. Arthritis Rheum 2001;44:2371-5.
32. Hengstman G, van den Hoogen F, ven Engelen B, et al. Anti-TNF blockade with infliximab (Remicade) in polymyositis and dermatomyositis. Arthritis Rheum 2000;43(suppl):S193 (abs 748).
33. Ellman MH, MacDonald PA, Hayes FA. Etanercept S. treatment for diffuse scleroderma: A pilot study. Arthritis Rheum 2000;43(suppl):S392 (abs 1955).
34. Schiff M, Mease P, Weinblatt M, et al. Randomized controlled trial of 25 mg vs. 50 mg enbrel (etanercept) twice weekly in rheumatoid arthritis (RA). Arthritis Rheum 2000;43(suppl):S391 (abs 1947).
35. Genovese M, Martin R, Fleischmann R, et al. Enbrel (etanercept) vs methotrexate (MTX) in early rheumatoid arthritis (ERA trial): Two-year follow-up. Arthritis Rheum 2000;43(suppl):S269 (abs 1217).
36. Shergy WJ, Phillips Jr RM, Hunt RE, Hernandez J. Safety and efficacy of infliximab therapy after etanercept failure: A case series. Arthritis Rheum 2001;44(suppl):S81 (abs 174).
37. Maksymowych WP, Mallon C, Spady B, Peerani R, and the Alberta Capital Health Region. Intent in rheumatoid arthritis prospective observational inception cohort: Efficacy, adverse events and withdrawal. Arthritis Rheum 2001;44(suppl):S82 (abs 175).
38. Wassermann MJ, Weber D, Bykerk V, Lee P, Keystone EC. Efficacy of infliximab (3 mg per kilogram) in a population of severe, long-standing RA patients treated in a of quarternary care center. Arthritis Rheum 2001;44(suppl):S82 (abs 177).
39. Van Vollenhoven RF, Gullstrom E, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice. Data from the Stockholm TNF alpha registry. Arthritis Rheum 2001;44(suppl):S82 (abstract 178).
40. Antoni CE, Furst D, Manger B, Lichtenstein GR, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease or rheumatoid arthritis. Arthritis Rheum 2001;44(suppl):S152 (abs 600).
41. Hanauer SB. Review article: Safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999;13:16-22.
42. Keane J, Gershom S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med 2001;345:1098-104.
43. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during antitumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
44. Peterson JR, Wener MH, Hsu FC, Simkin PA. Safety of TNF alpha antagonists in patients with rheumatoid arthritis and chronic hepatitis C. Arthritis Rheum 2001;44(suppl):S78 (abs 156).
45. Schiff MH, Bulpitt K, Weaver AA, Genovese M, Cohen S, Furst DE, et al. Safety of combination therapy with anakinra and etanercept in patients with rheumatoid arthritis. Arthritis Rheum 2001;44(suppl):S79 (abs 157).
46. Breshnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domijan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
47. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt M, Moreland LW, et al. Treatment of rheumatoid arthritis with Anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Arthritis Rheum 2002;46:614-24.
48. Fleischman R, Tesser J, Schechtman J, Modaferri D, Poulakos J, Bennett R, et al. A safety trial of Anakinra, recombinant IL-1ra, in a large, placebo controlled, heterogenous population of patients with rheumatoid arthritis. Arthritis Rheum 2001;44(suppl):S84 (abs 190).
49. Dayer J-M, Breshnihan B. Targeting interleukin-1 in the treatment of rheumatoid arthritis. Arthritis Rheum 2002;46:574-8.
50. Cohen S, Nakelsky S, Mulani P, Badamgarav E, Harada A, Sokolskiy L, et al. The impact of Anakinra therapy on patient centered outcomes in rheumatoid arthritis. Arthritis Rheum 2001;44(suppl):S77 (abs 149).
51. Jian Y, Genant HK, Watt I, Cobby M, Breshnihan B, Aitchison R, McCabe D. A multicenter, double-blind, dose ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.